Fluad is a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B).
Fluad is specifically indicated for the prevention of seasonal influenza in people 65 years of age and older.
Fluad is supplied as a solution for intramuscular injection. The recommended dose is a single 0.5 mL dose.
The FDA approval of Fluad was based on a safety and immunogenicity study of Fluad in comparison to Agriflu. A total of 7,082 subjects were randomized and vaccinated with Fluad or Agriflu. The primary immunogenicity analyses were conducted on all vaccinated subjects with a blood sample collected at Day 22. Non-inferiority of Fluad compared with Agriflu was demonstrated for all three vaccine strains based on pre-defined thresholds for seroconversion rate differences and GMT ratios.
Adverse effects associated with the use of Fluad may include, but are not limited to, the following:
local (injection site) adverse reactions:
systemic adverse reactions
Fluad is a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B). It is manufactured using an egg-based process and is formulated with the adjuvant MF59, an oil-in-water emulsion of squalene oil.
For additional information regarding Fluad or influenza A and B in older individuals, please visit http://www.seqirus.com/